ORCID Profile
0000-0002-6497-2963
Current Organisations
Rigshospitalet Neurocentret
,
European Research Council
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Elsevier BV
Date: 07-2021
DOI: 10.1016/J.JCLINEPI.2021.01.023
Abstract: To develop and validate Clinical Diversity In Meta-analyses (CDIM), a new tool for assessing clinical ersity between trials in meta-analyses of interventions. The development of CDIM was based on consensus work informed by empirical literature and expertise. We drafted the CDIM tool, refined it, and validated CDIM for interrater scale reliability and agreement in three groups. CDIM measures clinical ersity on a scale that includes four domains with 11 items overall: setting (time of conduct/country development status/units type) population (age, sex, patient inclusion criteria/baseline disease severity, comorbidities) interventions (intervention intensity/strength/duration of intervention, timing, control intervention, cointerventions) and outcome (definition of outcome, timing of outcome assessment). The CDIM is completed in two steps: first two authors independently assess clinical ersity in the four domains. Second, after agreeing upon scores of in idual items a consensus score is achieved. Interrater scale reliability and agreement ranged from moderate to almost perfect depending on the type of raters. CDIM is the first tool developed for assessing clinical ersity in meta-analyses of interventions. We found CDIM to be a reliable tool for assessing clinical ersity among trials in meta-analysis.
No related grants have been discovered for Maria Louise Fabritius.